問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Infectious Disease

Division of General Internal Medicine

更新時間：2024-06-04

張上淳Chang, Shan-Chwen
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • ntuvpmed@ntu.edu.tw

Recruiting Trial

4Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張上淳

List

27Cases

2007-03-01 - 2008-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-09-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2008-03-01 - 2011-05-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-08-20 - 2021-05-06

Phase I

A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers

  • Condition/Disease

    COVID-19 prevention

  • Test Drug

    AdimrSC-2f (SARS-COV-2)

Participate Sites
1Sites

Recruiting1Sites

2017-10-01 - 2021-12-31

Phase II

Phase II, Randomized, Double-blind, Clinical Tial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan

  • Condition/Disease

    Dengue

  • Test Drug

    tetravalent live attenuated dengue vaccine admixture TV005

Participate Sites
4Sites

Not yet recruiting2Sites

Terminated1Sites

陳彥旭
Kaohsiung Municipal Gangshan Hospital

未分科

2015-04-01 - 2016-06-30

Phase I/II

A Phase I/II, Prospective, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of an Inactivated Cell Culture Derived H7N9 Influenza Vaccine in Healthy Adult Subjects

  • Condition/Disease

    H7N9 Influenza Vaccine

  • Test Drug

    AT-501

Participate Sites
3Sites

Terminated3Sites

2020-09-01 - 2022-01-31

Phase I

A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901

  • Condition/Disease

    COVID-19

  • Test Drug

    MVC-COV1901 vaccine (暫定)

Participate Sites
1Sites

Terminated1Sites

2012-03-31 - 2013-12-01

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Study ended5Sites

2023-01-01 - 2023-01-24

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2020-03-10 - 2020-09-22

Phase III

A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate COVID-19 Compared to Standard of Care Treatment

  • Condition/Disease

    moderate COVID-19

  • Test Drug

    Remdesivir 100 mg

Participate Sites
3Sites

Terminated3Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB